STOCK TITAN

Pliant Therapeutics (PLRX) awards 60,000 stock options to director Flavia Borellini

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PLIANT THERAPEUTICS, INC. director Flavia Borellini received a compensatory stock option grant covering 60,000 shares of common stock on July 9, 2026. The option has an exercise price of $1.13 per share and expires on July 9, 2036. Vesting occurs as 1/36th of the option each month starting on July 9, 2026, subject to her continued service, and all 60,000 option shares are reported as held directly after the award.

Positive

  • None.

Negative

  • None.
Insider Borellini Flavia
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 60,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 60,000 shares (Direct)
Footnotes (1)
  1. [object Object]
Option shares granted 60,000 shares Stock Option (Right to Buy) granted to director on July 9, 2026
Exercise price $1.13 per share Conversion or exercise price for the 60,000-share stock option
Expiration date July 9, 2036 Expiration of the granted stock option
Shares underlying option 60,000 shares Underlying common stock tied to the derivative security
Post-transaction derivative holdings 60,000 options Total stock options held directly by the reporting person after the grant
Stock Option (Right to Buy) financial
"security_title is listed as Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price is reported as 1.1300 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"1/36th of the shares subject to such option vest and become exercisable"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
derivative security financial
"transaction_type is derivative for the stock option grant"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What insider transaction did PLIANT THERAPEUTICS (PLRX) report for Flavia Borellini?

PLIANT THERAPEUTICS reported a stock option grant to director Flavia Borellini for 60,000 shares of common stock. The grant is a compensatory award, not an open-market purchase or sale, and is reported as a derivative security.

What is the exercise price and term of the new PLRX stock options granted to Flavia Borellini?

The granted stock option has an exercise price of $1.13 per share and an expiration date of July 9, 2036. This gives the director the right to buy up to 60,000 shares at $1.13 before that date, once vested.

How do the 60,000 PLRX stock options granted to Flavia Borellini vest?

The 60,000-share option vests in 36 equal monthly installments. Specifically, 1/36th vests each month on the monthly anniversary of July 9, 2026, conditioned on Borellini’s continuous service to PLIANT THERAPEUTICS on each vesting date.

How many PLRX derivative securities does Flavia Borellini hold after this Form 4 transaction?

After the reported transaction, Flavia Borellini holds 60,000 stock options directly. These options each relate to one share of common stock and are subject to the $1.13 exercise price and the stated vesting and expiration terms.

Does the PLRX Form 4 show any open-market buys or sells by Flavia Borellini?

The Form 4 shows no open-market purchases or sales. It reports only a compensatory grant/award acquisition of stock options coded as “A,” with no shares bought or sold in the market and net buy/sell direction noted as neutral.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Borellini Flavia

(Last)(First)(Middle)
C/O PLIANT THERAPEUTICS, INC.
331 OYSTER POINT BOULEVARD

(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
PLIANT THERAPEUTICS, INC. [ PLRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1.1307/09/2026A60,000 (1)07/09/2036Common Stock60,000$060,000D
Explanation of Responses:
1. 1/36th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of July 9, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.
Remarks:
/s/ Jennifer Woo, attorney-in-fact07/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)